SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 20,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total value of $138,400.00. Following the completion of the transaction, the chairman directly owned 3,472,822 shares of the company’s stock, valued at approximately $24,031,928.24. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total value of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Stock Down 7.9%

Shares of NASDAQ SOPH opened at $6.30 on Thursday. The company has a market capitalization of $528.51 million, a P/E ratio of -5.48 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company has a 50 day simple moving average of $5.54 and a 200-day simple moving average of $5.12. SOPHiA GENETICS SA has a 1 year low of $2.96 and a 1 year high of $7.21.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%. On average, equities research analysts predict that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. purchased a new stake in SOPHiA GENETICS during the second quarter worth about $567,000. Royal Bank of Canada boosted its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the period. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Principal Financial Group Inc. grew its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Finally, Hodges Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $2,157,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SOPH. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright upped their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.00.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its 2026 revenue outlook to $94 million–$96 million, above the approximately $93.4 million consensus estimate, implying 22%–24% year-over-year growth. Management also continues to target adjusted EBITDA breakeven by year-end. 2026 revenue outlook and EBITDA breakeven article
• Positive Sentiment: The company announced a multi-year global collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement could expand SOPH’s role in oncology testing and support longer-term revenue growth. AstraZeneca collaboration article
• Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and maintained a Buy rating, while BTIG lifted its target from $8 to $9 and also kept a Buy rating. The revisions indicate improving analyst confidence in SOPH’s growth outlook. Analyst price target updates
• Positive Sentiment: Second-quarter revenue increased 27% year over year to $23.3 million, exceeding expectations of $21.7 million, while the adjusted EBITDA loss improved 27% to $8.8 million. Second-quarter 2026 results article
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares for about $242,350 under pre-arranged Rule 10b5-1 plans. The sales reduced their holdings only modestly, limiting their signaling value.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, missing the $0.21-loss consensus estimate by $0.05. Net loss remained $22.4 million, and gross margin declined from the prior-year period, underscoring continuing profitability concerns. Quarterly earnings report

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.